이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Lupin 대차 대조표 상태

재무 상태 기준 확인 6/6

Lupin 의 총 주주 지분은 ₹143.7B 이고 총 부채는 ₹26.7B, 이는 부채 대 자기자본 비율을 18.6% 로 가져옵니다. 총자산과 총부채는 각각 ₹240.0B 및 ₹96.2B 입니다. Lupin 의 EBIT는 ₹26.0B 이며 이자보상배율은 8.4 입니다. ₹20.5B 의 현금 및 단기 투자금을 보유하고 있습니다.

주요 정보

18.6%

부채 비율

₹26.70b

부채

이자 보상 비율	8.4x
현금	₹20.49b
주식	₹143.73b
총 부채	₹96.24b
총 자산	₹239.97b

최근 재무 상태 업데이트

Recent updates

These 4 Measures Indicate That Lupin (NSE:LUPIN) Is Using Debt Safely

Jun 15

Analysts Are Updating Their Lupin Limited (NSE:LUPIN) Estimates After Its Annual Results

May 09

With EPS Growth And More, Lupin (NSE:LUPIN) Makes An Interesting Case

May 08

Investor Optimism Abounds Lupin Limited (NSE:LUPIN) But Growth Is Lacking

Apr 20

Here's Why Lupin (NSE:LUPIN) Can Manage Its Debt Responsibly

Mar 03

Earnings Beat: Lupin Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Feb 10

Lupin Limited's (NSE:LUPIN) Share Price Could Signal Some Risk

Jan 19

Is Lupin (NSE:LUPIN) Using Too Much Debt?

Nov 10

Is Lupin (NSE:LUPIN) Using Too Much Debt?

Jun 23

Here's Why Lupin (NSE:LUPIN) Can Manage Its Debt Responsibly

Mar 24

Lupin's (NSE:LUPIN) Dividend Is Being Reduced To ₹4.00

Jul 08

Is Lupin Limited (NSE:LUPIN) Worth ₹756 Based On Its Intrinsic Value?

Mar 27

Lupin (NSE:LUPIN) Could Easily Take On More Debt

Jan 22

재무 상태 분석

단기부채: LUPIN 의 단기 자산 ( ₹134.5B )이 단기 부채( ₹85.0B ).

장기 부채: LUPIN 의 단기 자산( ₹134.5B )이 장기 부채( ₹11.2B ).

부채 대 자본 내역 및 분석

부채 수준: LUPIN 의 순부채 대 자기자본 비율( 4.3% )은 satisfactory로 간주됩니다.

부채 감소: LUPIN 의 부채 대 자기자본 비율은 지난 5년간 61.6% 에서 18.6% 로 감소했습니다.

부채 범위: LUPIN 의 부채는 영업 현금 흐름 ( 136.6% )에 의해 잘 충당되었습니다.

이자 보장: LUPIN 의 부채에 대한 이자 지급은 EBIT( 8.4 x 적용 범위)로 잘 충당됩니다.

Lupin 대차 대조표 상태

재무 상태 기준 확인 6/6

주요 정보

최근 재무 상태 업데이트

These 4 Measures Indicate That Lupin (NSE:LUPIN) Is Using Debt Safely

Here's Why Lupin (NSE:LUPIN) Can Manage Its Debt Responsibly

Is Lupin (NSE:LUPIN) Using Too Much Debt?

Is Lupin (NSE:LUPIN) Using Too Much Debt?

Here's Why Lupin (NSE:LUPIN) Can Manage Its Debt Responsibly

Lupin (NSE:LUPIN) Could Easily Take On More Debt

Recent updates

These 4 Measures Indicate That Lupin (NSE:LUPIN) Is Using Debt Safely

Lupin Limited Announces Board Appointments

Analysts Are Updating Their Lupin Limited (NSE:LUPIN) Estimates After Its Annual Results

New minor risk - Dividend sustainability

With EPS Growth And More, Lupin (NSE:LUPIN) Makes An Interesting Case

Full year 2024 earnings: EPS misses analyst expectations

Lupin Limited to Report Q4, 2024 Results on May 06, 2024

Investor Optimism Abounds Lupin Limited (NSE:LUPIN) But Growth Is Lacking

Lupin Limited Announces Change in Management

Here's Why Lupin (NSE:LUPIN) Can Manage Its Debt Responsibly

Lupin Limited Launches Bromfenac Ophthalmic Solution, 0.075% in the United States

Earnings Beat: Lupin Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Price target increased by 12% to ₹1,355

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Lupin Limited Receives Approval from U.S. FDA for Bromfenac Ophthalmic Solution, 0.075%

Insufficient new directors

Lupin Limited to Report Q3, 2024 Results on Feb 07, 2024

Lupin Receives Approval from U.S. FDA for Febuxostat Tablets

Lupin Limited's (NSE:LUPIN) Share Price Could Signal Some Risk

Lupin Limited Launches Bromfenac Ophthalmic Solution, 0.07% in the United States

Lupin Receives Approval from U.S. FDA for Loteprednol Etabonate Ophthalmic Suspension, 0.2%

Lupin Limited Receives Tentative Approval from U.S. FDA for Canagliflozin Tablets

Lupin Limited Launches First Fixed-Dose Triple Combination Drug, Vilfuro-G® for COPD Management in India

Lupin Limited Receives Tentative Approval from U.S. FDA for Dapagliflozin Tablets

Price target increased by 8.2% to ₹1,067

Is Lupin (NSE:LUPIN) Using Too Much Debt?

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Lupin Limited to Report Q2, 2024 Results on Nov 08, 2023

Lupin Limited Receives Tentative Approval from U.S. FDA for Calcium, Magnesium, Potassium, and Sodium Oxybates Oral Solution

Lupin Limited (BSE:500257) completed the acquisition of Ondero and Ondero - Met from Boehringer Ingelheim International GmbH.

Price target increased by 15% to ₹878

Lupin Limited Approves Dividend for the Year Ended March 31, 2023

Girard Sharp LLP and Motley Rice LLC Announce a Proposed Settlement in re Xyrem (Sodium Oxybate) Antitrust Litigation

Girard Sharp LLP and Motley Rice LLC Announce a Proposed Settlement in In re Xyrem (Sodium Oxybate) Antitrust Litigation

Lupin Limited Receives Tentative Approval from U.S. Fda for Dolutegravir Lamivudine and Tenofovir Alafenamide Tablets

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Lupin Limited Receives EIR from U.S. FDA for its Pithampur Unit-2 Manufacturing Facility

Upcoming dividend of ₹4.00 per share at 0.4% yield

Lupin Limited, Annual General Meeting, Aug 03, 2023

Lupin Limited Receives Approval from U.S. Fda for Cyanocobalamin Nasal Spray

Is Lupin (NSE:LUPIN) Using Too Much Debt?

Lupin Limited Launches Thiamine Hydrochloride Injection USP in the United States

Lupin Launches Darunavir Tablets in the United States

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Here's Why Lupin (NSE:LUPIN) Can Manage Its Debt Responsibly

Third quarter 2023 earnings: Revenues in line with analyst expectations

Lupin Receives Approval from US FDA for Glycopyrrolate Injection, USP

Lupin Limited Receives Tentative Approval from U.S. FDA for Dolutegravir, Emtricitabine and Tenofovir Alafenamide (DETAF) Tablets

Lupin Limited to Report Q3, 2023 Results on Feb 09, 2023

Lupin Limited Launches Sacubitril and Valsartan Combination Drug for Heart Failure Patients

Lupin Receives Tentative Approval from U.S. FDA for Dolutegravir and Rilpivirine Tablets

Lupin and Exeltis Announce Reimbursement Approval of NaMuscla in Spain for the Symptomatic Treatment of Myotonia in Adults with Non-Dystrophic Myotonic Disorders

Lupin Receives Approval from U.S. FDA for Fesoterodine Fumarate Extended-Release Tablets

Lupin Limited Launches Novel Fixed-Dose Triple Drug Combination Difizma® Dpi to Treat Inadequately Controlled Asthma

Lupin Limited Announces Christine Mundkur Steps Down from Board of Directors, Effective January 1, 2023

Lupin Launches Rufinamide Tablets USP in the United States

Lupin Launches Formoterol Fumarate Inhalation Solution in the United States

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Lupin Receives Tentative Approval from U.S. FDA for Doxycycline Capsules

Lupin Limited Receives Tentative Approval from U.S. FDA for Drospirenone Tablets

Lupin Limited Update on its Biotech Manufacturing Facility

Lupin Announces Resignation of Kamal K. Sharma from the Board of Directors

Lupin Limited Appoints Shahin Fesharaki as Global Chief Scientific Officer

Lupin Receives Approval from U.S. FDA for Mirabegron Extended-Release Tablets

Lupin Receives Approval from U.S. FDA for Diclofenac Sodium Topical Solution USP, 2% w/w

Lupin Receives Health Canada Approval for Rymti® (Biosimilar Etanercept)

Lupin Launches Generic Suprep® Bowel Prep Kit in the United States

Lupin Limited in Partnership with Pharmascience Inc. Receives Tentative Approval from U.S. Fda for Dasatinib Tablets

Lupin Limited Announces Launch of Desvenlafaxine Extended-Release Tablets, 25 Mg